User:Aberesniak/sandbox

Ariel Beresniak (born 3 December 1961) is a Swiss specialist in Public Health and Health Economics, authors of reference books and scientific articles in modeling and decision-making analyses.

Biography
Ariel Beresniak is a Physician specialized in Public Health from the Faculty of Medicine at University of Marseille, France. Following his medical studies, he obtained a master's degree in Economics and a PhD in applied mathematics in Economics at the Claude-Bernard University (France). Subsequently, he obtained an Accreditation to Supervise Research (Habilitation a Diriger des Recherches). Ariel Beresniak was Head of Health Economics for Glaxo-Wellcome (1993-1999) and Global Head of Pharmacoeconomics for Serono-international (1999-2004). Since 2005, Ariel Beresniak is CEO of Data Mining International. Ariel Beresniak is expert-consultant for the World Health Organization and the European commission in the fields of Public health and Health Economics.

Scientific contribution
Ariel Beresniak is author of the reference book "Economie de la Santé" (Health Economics) published in French and Portuguese, "Dictionnaire commenté d'Economie de la Santé" ("Dictionnaire of Health Economics") published in French and Spanish, "Comprendre la Pharmacoecomomie ("Understanding Pharmacoeconomics") published in French and Japanese, "Dictionnaire Raisonné des termes des Entreprises de la santé" ("Dictionnary of terms used in health industries" published in French. Ariel Beresniak is also author and coauthors of 70 scientific articles in public health and health economics. Ariel Beresniak is known to have led the ECHOUTCOME project, a European Commission funded research, establishing that the QALY indicator (Quality Adjusted Life Years) is not scientifically validated to be used in Decision making and could lead to divergent results with the same dataset. These findings have generated an international controversy because the QALY indicator is still currently promoted as reference case by some national health technology assessment agencies such as the NICE (National Institute for Health and care Excellence) in the UK.